New-onset IgG autoantibodies in hospitalized patients with COVID-19

Abstract

COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein arrays to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients. Autoantibodies are identified in approximately 50% of patients but in less than 15% of healthy controls. When present, autoantibodies largely target autoantigens associated with rare disorders such as myositis, systemic sclerosis and overlap syndromes. A subset of autoantibodies targeting traditional autoantigens or cytokines develop de novo following SARS-CoV-2 infection. Autoantibodies track with longitudinal development of IgG antibodies recognizing SARS-CoV-2 structural proteins and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.

Cited by papers we hold 10

• Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics · 2023
  No notice
• Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study · 2023
  Corrected
• No increase in inflammation in late-life major depression screened to exclude physical illness · 2022
  Not checked
• From rare disorders of immunity to common determinants of infection: Following the mechanistic thread · 2022
  No notice
• Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system · 2022
  No notice
• Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study · 2022
  Not checked
• Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study · 2022
  Not checked
• The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies · 2022
  No notice
• Autoimmunity is a hallmark of post-COVID syndrome · 2022
  No notice
• Autoantibodies against type I IFNs in patients with critical influenza pneumonia · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.